Bao-Dong Qin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7660040/publications.pdf

Version: 2024-02-01

394421 265206 2,182 44 19 42 citations g-index h-index papers 45 45 45 3968 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cetuximab and vemurafenib plus FOLFIRIÂ(5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. European Journal of Cancer, 2022, 163, 152-162.	2.8	7
2	Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC. Lung Cancer, 2022, 170, 91-97.	2.0	1
3	Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncolmmunology, 2021, 10, 1929727.	4.6	32
4	Primary squamous cell carcinoma of pancreas: a population-based study. Gland Surgery, 2021, 10, 1029-1037.	1.1	4
5	Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report. JCO Precision Oncology, 2021, 5, 771-778.	3.0	8
6	Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 3236-3250.	2.8	4
7	Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. Annals of Translational Medicine, 2020, 8, 860-860.	1.7	9
8	<p>Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget's Disease Harboring Triple Uncommon HER2 Mutation: A Case Report</p> . OncoTargets and Therapy, 2020, Volume 13, 6289-6293.	2.0	7
9	The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Critical Reviews in Oncology/Hematology, 2020, 147, 102893.	4.4	33
10	Identification of clinical features to predict the consistency of mutational profiles obtained from plasma and tissue of advanced non-small cell lung cancer (NSCLC) patients Journal of Clinical Oncology, 2020, 38, e21537-e21537.	1.6	0
11	<p>MTSS1 inhibits metastatic potential and induces G2/M phase cell cycle arrest in gastric cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 5143-5152.	2.0	11
12	Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib. Journal of Thoracic Oncology, 2019, 14, e115-e117.	1.1	15
13	Basket Trials for Intractable Cancer. Frontiers in Oncology, 2019, 9, 229.	2.8	22
14	The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. Journal of Thoracic Disease, 2019, 11, 4507-4515.	1.4	27
15	Palbociclib for the Treatment of Metastatic Nasopharyngeal Carcinoma With CDK4 Amplification: A Case Report. JCO Precision Oncology, 2019, 3, 1-4.	3.0	2
16	Tumor mutation burden analysis in a 5,660 cancer patient cohort reveals cancer type-specific mechanisms for high mutation burden Journal of Clinical Oncology, 2019, 37, 2589-2589.	1.6	O
17	Primary pulmonary leiomyosarcoma: A population-based study. Lung Cancer, 2018, 116, 67-72.	2.0	28
18	Clinical, pathological and treatment factors associated with the survival of patients with primary pulmonary salivary gland-type tumors. Lung Cancer, 2018, 126, 174-181.	2.0	28

#	Article	IF	CITATIONS
19	Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy. Medical Hypotheses, 2018, 116, 111-113.	1.5	19
20	The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. OncoTargets and Therapy, 2018, Volume 11, 4739-4745.	2.0	23
21	Adenosquamous carcinoma of the bile duct: a population-based study. Cancer Management and Research, 2018, Volume 10, 439-446.	1.9	15
22	Gene expression profile of THP-1 cells treated with heat-killed Candida albicans. Annals of Translational Medicine, 2016, 4, 170-170.	1.7	4
23	Decreased expression of TIPE2 contributes to the hyperreactivity of monocyte to Tollâ€like receptor ligands in primary biliary cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1177-1183.	2.8	13
24	Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus. Journal of Clinical Laboratory Analysis, 2016, 30, 897-904.	2.1	17
25	Potentials of the elevated circulating miR-185 level as a biomarker for early diagnosis of HBV-related liver fibrosis. Scientific Reports, 2016, 6, 34157.	3.3	18
26	Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Modern Rheumatology, 2016, 26, 372-376.	1.8	281
27	Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer, 2015, 15, 615.	2.6	60
28	Response to:  Body mass index and the risk of rheumatoid arthritis: a systematic review and dose–response meta-analysis' - authors' reply. Arthritis Research and Therapy, 2015, 17, 217.	3.5	9
29	Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Research and Therapy, 2015, 17, 86.	3.5	162
30	Response to: â€~ls primary Sjögren's syndrome an orphan disease? A critical appraisal of prevalence studies in Europe' by Cornec and Chiche. Annals of the Rheumatic Diseases, 2015, 74, e26-e26.	0.9	1
31	A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes and Development, 2015, 29, 1271-1284.	5.9	278
32	The association of Tyro3/Axl/Mer signaling with inflammatory response, disease activity in patients with primary Sj \tilde{A} ¶gren's syndrome. Joint Bone Spine, 2015, 82, 258-263.	1.6	21
33	Polymyositis/dermatomyositis and Malignancy Risk: A Metaanalysis Study. Journal of Rheumatology, 2015, 42, 282-291.	2.0	141
34	Epidemiology of primary Sj \tilde{A} gren's syndrome: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1983-1989.	0.9	556
35	Prognostic value of neutrophil to lymphocyte ratio for gastric cancer. Annals of Translational Medicine, 2015, 3, 50.	1.7	16
36	Prognostic Value of Red Blood Cell Distribution Width for Patients with Heart Failure: A Systematic Review and Meta-Analysis of Cohort Studies. PLoS ONE, 2014, 9, e104861.	2.5	97

#	Article	lF	CITATIONS
37	The Association of 5-HT2A, 5-HTT, and LEPR Polymorphisms with Obstructive Sleep Apnea Syndrome: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e95856.	2.5	23
38	The association between Cytotoxic T Lymphocyte Associated Antigen-4, Fas, Tumour Necrosis Factor-α gene polymorphisms and autoimmune hepatitis: A meta-analysis. Digestive and Liver Disease, 2014, 46, 541-548.	0.9	14
39	Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjögren's syndrome. Clinical Biochemistry, 2014, 47, 287-290.	1.9	88
40	Analysis of altered <scp>microRNA</scp> expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 543-550.	2.8	38
41	The Association between TNF-α, IL-10 Gene Polymorphisms and Primary Sjögren's Syndrome: A Meta-Analysis and Systemic Review. PLoS ONE, 2013, 8, e63401.	2.5	26
42	Association of Human Leukocyte Antigen Class II with Susceptibility to Primary Biliary Cirrhosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e79580.	2.5	12
43	Effect of the polymorphisms of tumor necrosis factor- $\hat{l}\pm$ gene on the susceptibility to primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1386-1392.	1.6	4
44	Scientific Publications on Primary Biliary Cirrhosis from 2000 through 2010: An 11-Year Survey of the Literature. PLoS ONE, 2012, 7, e35366.	2.5	8